

Contents lists available at BioMedSciDirect Publications

International Journal of Biological & Medical Research

Journal homepage: www.biomedscidirect.com



Original Article

Prevalence and Antibiotic sensitivity pattern of *Pseudomonas aeruginosa*; an emerging nosocomial pathogen

^aMohan BS, ^bLava R, ^cPrashanth HV, ^dVinod Nambiar, ^eMetri Basavaraj, ^fNayak Venkatesh R, ^gBaragundi Mahesh, ^hSriKrishna R

^aAsst. Professor, Dept. of Microbiology, Saptagiri Institute of Medical Sciences, Bangalore

^bProfessor, Dept. of Microbiology, JJM Medical College, Davangere

^cAssoc. Professor, Oman medical college

^dProfessor, Siddhartha Medical College, Tumkur

^eAssoc Professor, BLDE medical college, Bijapur

^fAssoc. Professor, Raichur Medical College, Raichur

^gAssoc. Professor, Chennabasappa Institute of Medical Sciences, Bagalkote

^hAssoc. Professor, Siddhartha Medical College, Tumkur

ARTICLE INFO

Keywords:

Drug resistance

Acinetobacter baumannii

Nosocomial infection

ABSTRACT

To determine current trends of antibiotic resistance among clinically significant *Pseudomonas aeruginosa* strains causing various nosocomial and community acquired infections. A total of 158 clinical isolates of *P. aeruginosa* isolated in the Department of Microbiology, J.J.M. Medical College, Davangere were studied for its prevalence and susceptibility profiles. Most of the isolates were from pus (72) followed by urine (26), sputum (20), blood (16) and antral wash (10). The least number of isolates were obtained from endotracheal tube aspiration (6), aural swab (4), pleural fluid (2) and corneal scraping (2). *P. aeruginosa* infections were higher in males than females. The maximum numbers of isolates were from patients of age group 41-60 years. The in vitro sensitivity pattern of 158 isolates of *P. aeruginosa* showed highest sensitivity to imipenem (94.30%) followed by tobramycin (72.15%), amikacin (67.09%), piperacillin (64.55%), carbenicillin (62%), ceftazidime (59.5%), cephalexin (53.16%), ciprofloxacin (50.63%), ofloxacin (39.24%), Gentamycin (31.65%) and Ceftriaxone (31.65%). The results indicate that *P. aeruginosa* is the most common gram-negative bacterium responsible for the nosocomial as well as community acquired infections. The excessive use of antibiotics has not only led to treat the *P. aeruginosa* infections but also the emergence of antibiotic resistance. The development of multidrug resistant *P. aeruginosa* is currently one of the greatest challenges to the effective management of infections. This suggests that in addition to curative measures promptly preventive measures such as hygienic as well as better hospital and postoperative care in administration should be adopted.

© Copyright 2010 BioMedSciDirect Publications IJBMR -ISSN: 0976:6685. All rights reserved.

1. Introduction

Pseudomonas aeruginosa is a gram negative, asporogenous, obligate aerobic, motile and oxidase positive bacilli, usually found in the intestinal tract, water, soil and sewage. 1, 2,3, *P. aeruginosa* accounts for a significant proportion of nosocomial infections.4,5 A

general problem with nosocomial infections is the tendency of nosocomial pathogens to acquire new antibiotic resistance.6,7 Multidrug-resistant (MDR) strains of *P. aeruginosa* are often isolated among patients suffering from nosocomial infections, particularly those in the intensive care unit (ICU).8 Thus, infections caused by *P. aeruginosa* are particularly problematic because the organism is inherently resistant to many drug classes and is able to acquire resistance to all effective antimicrobial drugs.9 As an opportunistic infectious pathogen, *P. aeruginosa* can often lead to life-threatening diseases. For example, *P. aeruginosa* is the main cause of mortality in cases of polymicrobial

* Corresponding Author: **Khayati Sant Ram**

Dept of Anatomy, Hind institute of medical sciences

Assistant professor, Dept. of Anatomy

Hind institute of medical sciences

Safedabad, Barabanki, U.P, INDIA

E.mail: khayati_santram@yahoo.com

bacteraemia,10 and the second most common bacterium causing sepsis in the ICU.11 In addition, *P. aeruginosa* has been implicated in urinary tract infections, burn wounds, ventilator-associated pneumonia and multi-organ system failure.12-15

Therefore, it was important to study the susceptibility patterns of *P. aeruginosa* isolates to some commonly used antibiotics. Use of the antibiogram as an epidemiological indicator for our isolates can help us make the best use of these antimicrobial agents in the management of *P. aeruginosa* infections.

Aims and Objectives:

Despite the use of potent antibiotics still high mortality exists in case of *P. aeruginosa* infections. Nosocomial multidrug resistant *P. aeruginosa* is an important health care problem worldwide that prolongs the duration of hospitalization, thereby increasing the cost of patient care. Considering the problem of *P. aeruginosa* infection and multidrug antibiotic resistance in it, the present study has been carried out to determine current trends of antibiotic resistance among *P. aeruginosa* strains causing various nosocomial and community acquired infections.

2. Materials and Methods:

A total of 158 *P. aeruginosa* isolates from clinical samples such as pus, urine, sputum, blood, antral wash, aural swab, endotracheal tube aspirates and pleural fluid were identified and characterized on the basis of colony morphology and biochemical reactions according to Bergey's Manual of Determinative Bacteriology, 9th edition. All the isolates were tested for antibiotic sensitivity pattern by Kirby Bauer disc diffusion method. *P. aeruginosa* (ATCC27853) was used as a control strain. All the isolates were tested against Imipenem (10ug), tobramycin, piperacillin, ofloxacin (5ug), ciprofloxacin (5ug), amikacin (30ug), gentamicin (30ug), cephotaxime (30ug), ceftazidime (30ug), ceftriaxone (30ug) and carbenicillin (100ug). The plates were incubated at 37°C for 16-18 hours. After overnight incubation, plates were examined and zones of inhibition were measured. Results were interpreted on the basis of zone sizes, as sensitive, intermediate, resistant according to National Committee for Control Laboratory standards (NCCLS, 1993).

3. Results

A total of 158 isolates of *P. aeruginosa* isolated from various specimens (114 were isolated from males and 44 from females) are included in the present study. Out of these 158 samples of *P. aeruginosa*, 72 were isolated from pus, 26 from urine, 20 from sputum, 16 from blood, 10 from antral wash, 6 from endotracheal tube aspirates, 4 from aural swab and 2 each from pleural fluid and corneal scrapings (Table 3). Among 72 isolates of pus, 49 (68%) were from males and 23 (32%) were from females. Among 26 isolates of urine 18 (69.23%) were from females and 8 (30.77%) from males. Out of 20 isolates from sputum, 11 (55%) were from males and 9 (45%) were from females. In case of pus prevalence of *P. aeruginosa* was more in males (68%) as compared to females (32%). In case of urine the prevalence was higher in females (69.23%) as compared to males (30.77%).

Figure 1





Table 1 shows the susceptibilities of the 158 isolates. Three aminoglycosides, that is, tobramycin, Amikacin, and gentamycin were tested against *P. aeruginosa*. Out of these three aminoglycosides, amikacin showed 67.09% susceptibility, tobramycin showed 72.15% sensitivity and gentamycin showed 35.44% sensitivity. Among the fluoroquinolones, ciprofloxacin was found effective against 50.63% isolates and ofloxacin showed 39.24% sensitivity. Among 3rd generation cephalosporins, ceftazidime showed 59.5% sensitivity, Cefotaxime showed 53.16% sensitivity and ceftriaxone showed 31.65% sensitivity. Piperacillin showed 64.55% sensitivity while carbenicillin showed sensitivity to 62% of the isolates. Imipenem was found to be the most effective antibiotic among all the antibiotics used in this study. The percentage of sensitive organisms was 94.3%, whereas, only 5.7% were resistant to imipenem.

Table 1 - Sensitivity pattern of Pseudomonas aeruginosa isolated from clinical samples



4. Discussion

In our study a significant increase was found in the number of *P. aeruginosa* strains isolated from pus followed by urine and sputum. Similar pattern of isolation of *Paeruginosa* from pus, urine, sputum, blood, ear, nose, wound and other infection sites was reported by some other studies.16, 17 In the present study, uropathogenic *Paeruginosa* was found higher in females than males. The one reason may be that *Paeruginosa* may be a common inhabitant of lower intestinal tract and in female the distance between anal and vaginal opening is small, thus *Paeruginosa* through fecal contamination invade and colonized urinary tracts causing

infection. Longer stay in the hospital increases the colonization of skin and environment of the patient and may be responsible for higher incidence of Urinary catheter related infections. 18 In the present study, endotracheal tube aspirates, aural swabs, pleural fluid and corneal scrapings samples were so less to comment on, this may be due to the low number of endotracheal tube aspirates, aural swabs, pleural fluid and corneal scraping samples sent from wards and OPD's during the study period. *P. aeruginosa* is currently one of the most frequent nosocomial pathogen and the infections due to this organism are often difficult to treat due to antibiotic resistance.¹⁹

The mechanisms of resistance to antibiotics include reduced cell wall permeability, production of chromosomal and plasmid mediated β -lactamases²⁰, aminoglycoside-modifying enzymes²¹ and an active multidrug efflux mechanism²². In the present study, the sensitivity pattern of 158 clinical isolates of *P. aeruginosa*, showed highest resistance to ceftriaxone (68.35%) and gentamicin (64.66%). The next most resistant antibiotics were ofloxacin (60.76%), ciprofloxacin (49.37%), cephotoxime (46.84%), ceftazidime (40.5%), carbenicillin (38%), piperacillin (35.45%), amikacin (32.91%), tobramycin (27.85%) and imipenem (6.7%). Among most commonly used cephalosporins, ceftazidime and cephotoxime proved to be most effective against *Paeruginosa*, with resistant rate of (40.5%) and (46.84%), respectively. This finding is consistence with other findings.²³ An important striking feature found in this study was increased resistance to gentamycin (66%) whereas the strains were sensitive to amikacin and tobramycin. Various workers have also reported the increased sensitivity of *P. aeruginosa* strains to amikacin and resistance to gentamicin.^{16, 24} Majority of the *P. aeruginosa* strains from the present study were multiple antibiotic resistant, especially the isolates recovered from pus. Such multiple resistance patterns have also been documented earlier.⁹ Resistance means that people cannot be effectively treated and they remain ill for longer period of time. It also means that epidemics are prolonged and thus that there is a greater risk of infection to others. The development of resistance is accelerated when antimicrobials are misused. Despite the use of potent antibiotics still high mortality exists in case of *P. aeruginosa* infections. Nosocomial multidrug resistant *Paeruginosa* is an important health care problem worldwide. Antimicrobial resistance prolongs the duration of hospitalization, thereby, increasing the cost of patient care. There are multiple factors, which contribute to the global spread of resistance. Decreasing unnecessary antibiotic use, treating with narrow spectrum agents, improving compliance with therapy, decreasing use of antibiotic in animal and agriculture, and improving infection control all have a role in confronting this problem.

5. References:

- [1] Koneman EW, Allen Sd, Janda WM, Schreckenberger PC, Winn WC. The nonfermentative gram negative bacilli. In: Koneman's Colour atlas and text book of diagnostic microbiology. 5th ed. Philadelphia, USA : Lippincott, Williams and Wilkins Publications; 1997.p.254-309.
- [2] Cheesbrough, M (2002). District Laboratory practice in Tropical Countries, Part Cambridge University press.
- [3] Brooks, G.F., Butel, J.S and Moore, S.A (2004). Medical Microbiology. 23rd edition. Lange medical Books/McGraw Hill medical publishing, New York.
- [4] Blanc DS, Petignat C, Janin B, et al. Frequency and molecular diversity of *Pseudomonas aeruginosa* upon admission and during hospitalization: a prospective epidemiologic study. *Clin Microbiol Infect* (1998) 4:242-7.
- [5] Gerri S. Hall. Nonfermenting gram negative bacilli and miscellaneous gram negative rods. In : Mahon CR and Manuselis George, editors. Text book of diagnostic microbiology; 2nd ed. W.B. Saunders Company, USA; 2000 .p.540-561.
- [6] Livrelli V, De Champs C, Di Martino P, et al. Adhesive properties and antibiotic resistance of *Klebsiella*, *Enterobacter*, and *Serratia* clinical isolates involved in nosocomial infections. *J Clin Microbiol* (1996) 34:1963-9.
- [7] Forbes BA, Sahn DF, Weissfeld AS. *Pseudomonas*, *Burkholderia* and Similar organisms. In: Bailey and Scott's diagnostic microbiology. 11th ed. Mosby, 2002 .p.385-397.
- [8] Tassios PT, Gennimata V, Spaliara-Kalogeropoulou L, et al. Multiresistant *Pseudomonas aeruginosa* serogroup O:11 outbreak in an intensive care unit. *Clin Microbiol Infect* (1997) 3:621-8.
- [9] Gales AC, Jones RN, Turnidge J, et al. Characterization of *Pseudomonas aeruginosa* isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. *Clin Infect Dis* (2001) 32(Suppl 2):S146-55.
- [10] Marra AR, Bar K, Bearman GM, et al. Systemic inflammatory response syndrome in nosocomial bloodstream infections with *Pseudomonas aeruginosa* and *Enterococcus* species: comparison of elderly and nonelderly patients. *J Am Geriatr Soc* (2006) 54:804-
- [11] Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med* (2006) 34:344-53.
- [12] Harjai K, Mittal R, Chhibber S, et al. Contribution of Tamm-Horsfall protein to virulence of *Pseudomonas aeruginosa* in urinary tract infection. *Microbes Infect* (2005) 7:132-7.
- [13] Rello J, Allegri C, Rodriguez A, et al. Risk factors for ventilator-associated pneumonia by *Pseudomonas aeruginosa* in presence of recent antibiotic exposure. *Anesthesiology* (2006) 105:709-14.
- [14] Altoparlak U, Aktas F, Celebi D, et al. Prevalence of metallo- β -lactamase among *Pseudomonas aeruginosa* and *Acinetobacter baumannii* isolated from burn wounds and in vitro activities of antibiotic combinations against these isolates. *Burns* (2005) 31:707-10.
- [15] Guidet B, Aegerter P, Gauzit R, et al. Incidence and impact of organ dysfunctions associated with sepsis. *Chest* (2005) 127:942-51.
- [16] Veenu, Sikka R, and Arora DR. Isolation and susceptibility pattern of nonfermenting gram negative bacilli from clinical samples. *Ind J Med Microbiol* 1999; 17(1): 14-17.
- [17] Lolitha Madtha and K. Gopala Krishna Bhat. Nonfermenting gram negative bacilli infections in hospitalized children. *Ind Assoc Biomedical Scientists*.1999; 19(2):99-102.
- [18] Taneja N, Meharwal SK, Sharma SK, and Sharma M. Significance and characterization of *Pseudomonads* from urinary tract specimens. *J Commun Dis* 2004 Mar; 36(1): 27-34.
- [19] Emori TG, Gaynes RP (1993). An overview of nosocomial infections, including the role of the microbiology laboratory. *Clin. Microbiol. Rev.* 6(4): 428-442.
- [20] Livermore DM (1989). Role of Beta-lactamase and impermeability in the resistance of *P. aeruginosa*. *Antibiot. Chemother.* 42: 257-263.
- [21] Livermore DM (1987). Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. *Eur. J. Clin. Microbiol.* 6: 439-445.
- [22] Li XZ, Livermore DM, Nikaido H (1994). Role of efflux pump(s) in intrinsic resistance of *P. aeruginosa*: resistance to tetracycline, chloramphenicol and norfloxacin. *Antimicrob. Agents Chemother.* 38(8): 1732-1741.
- [23] Gencer S, Benzonana N, Batirel A, Ozer S (2002). Susceptibility patterns and cross-resistance of antibiotics against *P. aeruginosa* is a teaching hospital of Turkey. *Annal. Clin. Microbiol. Antimicrob.* 1(1):2.
- [24] Nagoba D, Ulka G, and Gude. In vitro susceptibility of *Pseudomonas aeruginosa* to different antibiotics. *Indian J Med Microbiol* 1997; 15(4): 185-186.